Stock-Based Compensation
The latest quarterly stock-based comp is $21.30 Million with a quarter-over-quarter change of +4.93%. Stock-Based Compensation (SBC) is the expense recognized for equity awards (stock options, RSUs) granted to employees. It's a non-cash expense that dilutes existing shareholders.
PODD Stock-Based Comp
Reported quarterly stock-based compensation; no daily interpolation.
Current Stock-Based Comp
$21.30M
$21.30 Million
Quarter-over-Quarter Change
+4.93%
vs. $20.30M prior quarter
Historical Data
78
Quarters of data available
Quarterly Stock-Based Comp History
| Period | Stock-Based Comp | QoQ Change | % Change |
|---|---|---|---|
| Q1 2026 | $21.30M | +$1.00M | +4.93% |
| Q4 2025 | $20.30M | +$3.60M | +21.56% |
| Q3 2025 | $16.70M | +$9.20M | +122.67% |
| Q2 2025 | $7.50M | $-10.70M | -58.79% |
| Q1 2025 | $18.20M | $-1.80M | -9.00% |
| Q4 2024 | $20.00M | +$1.90M | +10.50% |
| Q3 2024 | $18.10M | +$1.10M | +6.47% |
| Q2 2024 | $17.00M | +$2.80M | +19.72% |
| Q1 2024 | $14.20M | +$1.60M | +12.70% |
| Q4 2023 | $12.60M | +$2.10M | +20.00% |
| Q3 2023 | $10.50M | $-2.60M | -19.85% |
| Q2 2023 | $13.10M | +$1.00M | +8.26% |
| Q1 2023 | $12.10M | +$900,000 | +8.04% |
| Q4 2022 | $11.20M | +$2.20M | +24.44% |
| Q3 2022 | $9.00M | $-2.20M | -19.64% |
| Q2 2022 | $11.20M | +$1.70M | +17.89% |
| Q1 2022 | $9.50M | +$900,000 | +10.47% |
| Q4 2021 | $8.60M | +$400,000 | +4.88% |
| Q3 2021 | $8.20M | $-800,000 | -8.89% |
| Q2 2021 | $9.00M | +$400,000 | +4.65% |
| Q1 2021 | $8.60M | $-7.00M | -44.87% |
| Q4 2020 | $15.60M | +$9.00M | +136.36% |
| Q3 2020 | $6.60M | +$800,000 | +13.79% |
| Q2 2020 | $5.80M | $-2.10M | -26.58% |
| Q1 2020 | $7.90M | $-96,000 | -1.20% |
| Q4 2019 | $8.00M | +$1.40M | +21.15% |
| Q3 2019 | $6.60M | $-1.70M | -20.48% |
| Q2 2019 | $8.30M | +$2.50M | +43.10% |
| Q1 2019 | $5.80M | $-516,000 | -8.17% |
| Q4 2018 | $6.32M | $-9.77M | -60.74% |
| Q3 2018 | $16.09M | +$9.15M | +131.95% |
| Q2 2018 | $6.94M | $-1.25M | -15.22% |
| Q1 2018 | $8.18M | $-209,000 | -2.49% |
| Q4 2017 | $8.39M | $-506,000 | -5.69% |
| Q3 2017 | $8.90M | +$1.36M | +18.13% |
| Q2 2017 | $7.53M | +$407,000 | +5.71% |
| Q1 2017 | $7.12M | +$357,000 | +5.28% |
| Q4 2016 | $6.77M | +$701,000 | +11.56% |
| Q3 2016 | $6.07M | +$553,000 | +10.03% |
| Q2 2016 | $5.51M | +$242,000 | +4.59% |
| Q1 2016 | $5.27M | $-55,000 | -1.03% |
| Q4 2015 | $5.33M | +$1.10M | +26.15% |
| Q3 2015 | $4.22M | $-103,000 | -2.38% |
| Q2 2015 | $4.33M | $-980,000 | -18.47% |
| Q1 2015 | $5.30M | +$1.03M | +24.18% |
| Q4 2014 | $4.27M | $-5.40M | -55.82% |
| Q3 2014 | $9.67M | +$5.45M | +129.31% |
| Q2 2014 | $4.22M | $-143,000 | -3.28% |
| Q1 2014 | $4.36M | +$1.48M | +51.23% |
| Q4 2013 | $2.88M | $-73,000 | -2.47% |
| Q3 2013 | $2.96M | $-893,000 | -23.20% |
| Q2 2013 | $3.85M | +$854,000 | +28.51% |
| Q1 2013 | $3.00M | +$575,000 | +23.76% |
| Q4 2012 | $2.42M | +$75,000 | +3.20% |
| Q3 2012 | $2.35M | $-201,000 | -7.89% |
| Q2 2012 | $2.55M | $-63,000 | -2.41% |
| Q1 2012 | $2.61M | +$481,000 | +22.60% |
| Q4 2011 | $2.13M | +$338,000 | +18.88% |
| Q3 2011 | $1.79M | $-65,000 | -3.50% |
| Q2 2011 | $1.85M | $-106,000 | -5.41% |
| Q1 2011 | $1.96M | +$854,000 | +77.15% |
| Q4 2010 | $1.11M | $-165,000 | -12.97% |
| Q3 2010 | $1.27M | $-102,000 | -7.42% |
| Q2 2010 | $1.37M | +$63,000 | +4.81% |
| Q1 2010 | $1.31M | +$294,000 | +28.91% |
| Q4 2009 | $1.02M | +$63,000 | +6.60% |
| Q3 2009 | $954,000 | $-76,000 | -7.38% |
| Q2 2009 | $1.03M | $-171,000 | -14.24% |
| Q1 2009 | $1.20M | +$1.20M | — |
| Q4 2008 | $0 | +$0 | — |
| Q3 2008 | $0 | +$0 | — |
| Q2 2008 | $0 | +$0 | — |
| Q1 2008 | $0 | +$0 | — |
| Q4 2007 | $0 | +$0 | — |
| Q3 2007 | $0 | +$0 | — |
| Q2 2007 | $0 | +$0 | — |
| Q1 2007 | $0 | +$0 | — |
| Q4 2006 | $0 | — | — |
Related Metrics
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy